ETH 47
Alternative Names: ETH-47Latest Information Update: 28 Apr 2025
At a glance
- Originator ethris
- Developer Ethris
- Class Antivirals; RNA
- Mechanism of Action Immunomodulators; Interferon type III expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Respiratory tract infections
- No development reported COVID 2019 infections; Influenza A virus infections
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in Germany (Inhalation)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Influenza-A-virus-infections in Germany (Inhalation)
- 30 Jan 2025 Ethris files a Clinical Trial Application (CTA) for a phase IIa rhinovirus challenge trial in asthma patients